Amphastar Pharmaceuticals 

€42.82
234
+€0+0% Hari ini

Statistik

Harga Tertinggi Hari Ini
42.82
Harga Terendah Hari Ini
42.82
52M Tinggi
-
52M Rendah
-
Volume
0
Rata-Rata Volume
-
Kap Pasar
2.39B
Rasio P/E
15.47
Hasil Dividen
-
Dividen
-

Mendatang

Pendapatan

4NovDiharapkan
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Berikutnya
0.48
0.7
0.93
1.15
EPS yang Diharapkan
1.008333
EPS Aktual
T/A

Orang Juga Mengikuti

Daftar ini didasarkan pada daftar pantauan orang-orang di Stock Events yang mengikuti 29A.F. Ini bukan rekomendasi investasi.

Peserta

Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.

Peringkat Analis

66Rata-Rata Target Harga
Perkiraan tertinggi adalah €66.
Dari 2 peringkat dalam 6 bulan terakhir. Ini bukan rekomendasi investasi.
Beli
50%
Tahan
50%
Jual
0%

Tentang

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Show more...
CEO
Dr. Ziping Luo Ph.D.
Karyawan
1761
Negara
US
ISIN
US03209R1032
WKN
000A11664

Daftar